Martin Gulliford1,2, Rathi Ravindrarajah1, Shota Hamada1,3, Stephen Jackson4, Judith Charlton1. 1. King's College London, Department of Primary Care and Public Health Sciences, London, UK. 2. National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust, London, UK. 3. Research Department, Institute for Health Economics and Policy, Association for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan. 4. King's College London, Department of Clinical Gerontology, London, UK.
Abstract
Objective: statin use over the age of 80 years is weakly evidence-based. This study aimed to estimate rates of statin inception and deprescribing by frailty level in people aged 80 years or older. Methods: a cohort of 212,566 participants aged ≥80 years was sampled from the UK Clinical Practice Research Datalink. Statin inception was defined as a first-ever prescription in a non-statin user; deprescribing was defined as a last ever statin prescription more than 6 months before the end of participant records. Rates were estimated in a time-to-event framework allowing for mortality as a competing risk. Co-variates were age, gender, frailty category and prevention type. Results: prevalent statin use increased from 2001-5 (9.9%) to 2011-15 (49.3%). Inception of statins in never-users was low overall at 2.4% per year (95% confidence interval (CI) 2.2-2.6%) and declined with age. Deprescribing of statins in current users occurred at a rate of 5.6% (95% CI 5.4-5.9%) per year overall and increased with age, reaching 17.8% per year (95% CI 6.7-28.9%) among centenarians. Deprescribing was slightly higher for primary prevention (6.5% per year) than secondary prevention (5.2% per year) indications (P < 0.001). Deprescribing increased with frailty level being 5.0% per year in 'fit' participants and 7.1% in 'severe' frailty (P < 0.001). Conclusions: statin use has increased in the over 80s but deprescribing is common and increases with age and frailty level. These paradoxical findings highlight a need for better evidence to inform statin use and discontinuation for people aged ≥80 years.
Objective: statin use over the age of 80 years is weakly evidence-based. This study aimed to estimate rates of statin inception and deprescribing by frailty level in people aged 80 years or older. Methods: a cohort of 212,566 participants aged ≥80 years was sampled from the UK Clinical Practice Research Datalink. Statin inception was defined as a first-ever prescription in a non-statin user; deprescribing was defined as a last ever statin prescription more than 6 months before the end of participant records. Rates were estimated in a time-to-event framework allowing for mortality as a competing risk. Co-variates were age, gender, frailty category and prevention type. Results: prevalent statin use increased from 2001-5 (9.9%) to 2011-15 (49.3%). Inception of statins in never-users was low overall at 2.4% per year (95% confidence interval (CI) 2.2-2.6%) and declined with age. Deprescribing of statins in current users occurred at a rate of 5.6% (95% CI 5.4-5.9%) per year overall and increased with age, reaching 17.8% per year (95% CI 6.7-28.9%) among centenarians. Deprescribing was slightly higher for primary prevention (6.5% per year) than secondary prevention (5.2% per year) indications (P < 0.001). Deprescribing increased with frailty level being 5.0% per year in 'fit' participants and 7.1% in 'severe' frailty (P < 0.001). Conclusions: statin use has increased in the over 80s but deprescribing is common and increases with age and frailty level. These paradoxical findings highlight a need for better evidence to inform statin use and discontinuation for people aged ≥80 years.
Authors: Kenneth Rockwood; Xiaowei Song; Chris MacKnight; Howard Bergman; David B Hogan; Ian McDowell; Arnold Mitnitski Journal: CMAJ Date: 2005-08-30 Impact factor: 8.262
Authors: Jonathan Afilalo; Gustavo Duque; Russell Steele; J Wouter Jukema; Anton J M de Craen; Mark J Eisenberg Journal: J Am Coll Cardiol Date: 2008-01-01 Impact factor: 24.094
Authors: Martin C Gulliford; Judith Charlton; Mark Ashworth; Anthony G Rudd; Andre Michael Toschke Journal: PLoS One Date: 2009-09-24 Impact factor: 3.240
Authors: Carolyn T Thorpe; Florentina E Sileanu; Maria K Mor; Xinhua Zhao; Sherrie Aspinall; Mary Ersek; Sydney Springer; Joshua D Niznik; Michelle Vu; Loren J Schleiden; Walid F Gellad; Jacob Hunnicutt; Joshua M Thorpe; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2020-08-12 Impact factor: 5.562
Authors: Geert J Lefeber; Huiberdina L Koek; Patrick C Souverein; Marcel L Bouvy; Anthonius de Boer; Wilma Knol Journal: J Am Geriatr Soc Date: 2019-10-24 Impact factor: 5.562
Authors: T Tannou; E Menand; D Veillard; J Berthou Contreras; C Slekovec; V Daucourt; D Somme; A Corvol Journal: BMC Geriatr Date: 2021-12-15 Impact factor: 3.921
Authors: Wade Thompson; Lucas Morin; Dorte Ejg Jarbøl; Jacob Harbo Andersen; Martin Thomsen Ernst; Jesper Bo Nielsen; Peter Haastrup; Morten Schmidt; Anton Pottegård Journal: JAMA Netw Open Date: 2021-12-01